Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results

Sana Biotechnology (NASDAQ:SANA) issued its earnings results on Friday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01, Zacks reports.

Sana Biotechnology Trading Down 3.8 %

Shares of SANA traded down $0.11 during mid-day trading on Monday, hitting $2.89. 1,981,002 shares of the company traded hands, compared to its average volume of 2,151,145. The stock has a market capitalization of $642.93 million, a price-to-earnings ratio of -2.29 and a beta of 1.44. The business has a 50-day moving average of $4.21 and a 200 day moving average of $5.77. Sana Biotechnology has a one year low of $2.76 and a one year high of $12.00.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a research report on Monday. Finally, Citigroup lifted their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

Insider Buying and Selling

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is currently owned by corporate insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.